When a Neuroscience Name Wakes Up, Don’t Sleep on this Stock

Some stocks slap you awake with a big green candle and a bigger question: is this the start of a new chapter, or just a caffeine rush?

Today, we’re talking about a neurologic heavyweight perking up, and why you should dive deeper into it.

Patterns Setting Up (Sponsored)

5 Stocks With Strong Patterns Setting Up

The difference between “nice returns” and life-changing gains often comes down to timing—and information.

Our latest research has identified 5 stocks positioned for massive growth.

These companies combine strong fundamentals with technical setups that suggest the potential for explosive upside.

Past editions of this same report have included stocks that went on to gain +175%, +498%, even +673%.¹

While the past can’t predict the future, the track record speaks volumes. For a limited time, you can download the full 5 Stocks Set to Double report—absolutely free.

Smart investors know: when the window is short, action beats hesitation.

[Get your free copy before midnight tonight] 

*This free resource is being sent by Zacks. We identify investment resources you may choose to use in making your own decisions. Use of this resource is subject to the Zacks Terms of Service.
*Past performance is no guarantee of future results. Investing involves risk. This material does not constitute investment, legal, accounting, or tax advice. Zacks Investment Research is not a licensed dealer, broker, or investment adviser.

Never Miss a Stock Alert Again!

We now send our daily picks via SMS too — so you’ll get the same high-conviction ideas, even if you miss the email.

👉 Click here to get stock picks by text and stay in the loop, always.

Intel | INTC

Price: $37.31

Intel’s stock got a jolt on chatter that key rival AMD could become a foundry customer. Even if early-stage, that headline says the quiet part out loud.

The U.S. fab rebuild is real, and customers want a second source onshore for anything below bleeding-edge nodes.

Layer in CHIPS tailwinds, government-friendly optics, and a growing roster of design wins for less complex silicon, and you’ve got a foundry story that no longer looks theoretical.

Now the grown-up part for you, with yields, timelines, and economics.

Intel still has to prove it can hit process roadmaps, deliver competitive cost per wafer, and avoid the margin black hole that can swallow good intentions.

Capex is heavy, free cash flow will be lumpy. But even incremental external wafers from marquee names can validate the model and compress the show me discount.

Treat INTC as a rebuild compounder. Buy partials on dips toward support and add if management prints sequential improvements in foundry revenue, external customer count, and node milestones.

Hedge the tech tape if you’re sizing up, as semis don’t move in straight lines.

Why it matters to you: You’re not paying AI-GPU multiples, you’re buying a supply-chain hedge with policy tailwinds and call options on an American foundry comeback.

Dollar Tree | DLTR

Price: $90.25

Dollar Tree is doing the boring work that compounds, converting stores to multi-price 3.0 formats, widening assortments, and grabbing market share in both consumables and discretionary.

Traffic is up, repeat visits are up, and comps have breadth, with party, seasonal, small hardware, even electronics.

Conversions are pacing to cover about half the fleet by year-end, and new distribution investments should ease in-stock headaches that used to kneecap growth.

Risks are that shrink is still a thing, multi-price needs tight execution to avoid customer whiplash, and the value consumer can be fickle if gas spikes or benefits roll off.

But the mix shift lifts tickets, and scale makes private label and logistics more profitable over time.

Watch gross margin, not just comps, as the real test is flow-through.

You can accumulate the stock on pullbacks toward the 100-day when retail gets de-risked. Add if you see two straight quarters of conversion-driven margin lift and SG&A discipline.

Optional trade is to pair DLTR long with a weaker discretionary retailer to neutralize macro wobbles.

Why it matters to you: In a higher-for-longer world, value retail is a steady friend. DLTR gives you defensiveness with self-help upside.

Market Edge Now(Sponsored)

A Free Guide to 2025’s Closing Rally Plays

The clock is ticking.

2025’s final quarter could be the last big rally before the reset of 2026.

Markets are moving fast:

• Fed signals hint at cuts

• Oil shocks roil supply chains

• AI & defense spending explode

We’ve zeroed in on 7 stocks primed to surge before year-end.

This isn’t noise, it’s your shot to finish 2025 ahead of the crowd.

But wait too long, and Wall Street takes it first.

[Claim Your Free “Top 7 Stocks for Q4 2025” Guide Now]

Paycom | PAYC

Price: $201.43

HR software rarely trends, but balance sheets notice. Paycom’s thesis is simple.

Single-database payroll and HCM that reduces admin drag, with high gross margins when onboarding and customer success run tight.

The backdrop includes consolidation chatter across the category, which adds a kicker to the operating story even if nothing happens near term.

What you own here, if you own it, is recurring revenue with pricing power once the seat count is sticky.

To turn the flywheel, they need to show net revenue retention holding up, RPO growth, and operating leverage reappearing as sales efficiency improves.

Competition remains real, think Dayforce, ADP, Paylocity, so keep a sharp eye on win rates in mid-market and churn in macro-sensitive cohorts.

Cash generation matters more than headline growth this late in the cycle. Start with a pilot allocation.

Add only if you see a clean print like a beat/raise, opex control, and evidence that AI-driven features are driving attach, not just sizzle.

Use a soft stop below recent base. Software can be volatile.

Why it matters to you: PAYC can be a quiet compounding engine in portfolios that need software exposure without mega-cap concentration risk.

Quest Diagnostics | DGX

Price: $181.00

Quest is tucking itself deeper into the clinical workflow with a multi-year Epic collaboration.

That means fewer frictions for ordering, billing, results, and patient scheduling across 2,000 service centers, plus tighter data pipes to payers and providers.

Add Haystack’s minimal residual disease testing push and a new JV in Michigan, and you’ve got a lab leader leaning into higher-value oncology and a cleaner consumer experience.

This is not a hypergrowth story, it’s a scale moat story. The levers are volume, mix, and reimbursement.

As processes consolidate on Epic’s diagnostic stack, Quest should harvest cost per requisition improvements and better denial management, both margin-friendly.

The long-run kicker is precision diagnostics, where payor coverage expands as evidence stacks.

Your game plan here can be to buy pullbacks for a defensive core. Track unit volumes, payer mix, and ongoing EPS guidance relative to non-recurring items.

If operating margin grinds higher 30–50 bps alongside stable cash returns, you’re getting paid to wait.

Why it matters to you: DGX is a strong company with optionality of healthcare volumes, steady cash flow, and a measured tilt toward higher-complexity testing.

Biogen | BIIB

Price: $155.25

Biogen’s move higher wasn’t just noise. They had beats on EPS and revenue, plus cleaner guidance, pushed the stock back into the conversation.

Under the hood, you’ve got a classic value-with-a-pipeline, with durable MS and neurology cash flows, cost discipline, and optionality from Alzheimer’s and next-gen neuro programs.

The balance sheet isn’t stretched, and mid-teens EPS guidance gives you a valuation bridge while the street debates what’s cyclical versus structural.

The swing factor is execution across a few tight turns. Ramp quality for newer launches, label and coverage dynamics in neurodegeneration, and how fast legacy erosion is offset by pipeline adds.

Keep an eye on gross margin trajectory and R&D productivity, two quarters of stable margins with pipeline milestones tends to pull multiples up from value land.

Start a core position on red days toward the 50-day, then add on confirmation. Think sustained closes above recent highs with volume.

Triggers to track are script trends, CMS/reimb updates, and any signal of partner economics improving.

Why it matters to you: If you want healthcare exposure that’s more than a dividend and less than a moonshot, BIIB is a pragmatic middle lane with rerate potential.

Today’s basket balances brains and budgets. Biogen offers a value-tilted rerate with pipeline torque.

Intel is the methodical rebuild with policy wind at its back. Dollar Tree is an operational self-help in the value aisle. Paycom is a selective software add for recurring revenue purists. 

Quest is defensive cash flow getting more efficient with every requisition.

Mix and match based on your risk sleeve, two defensives, two growths, and one catalyst-driven bio gives you a portfolio that can sip volatility without spilling it.

Stat of the Day: 28 Record Highs (and counting)

Equities keep setting fresh marks, 28 new closing highs on the S&P 500 so far this year, while the Fed keeps easing despite Chair comments that valuations are on the rich side. 

That doesn’t mean to chase every breakout. You might just want to tighten risk management.

Own pricing power, keep some cash for pullbacks, and balance momentum with businesses that can defend margins if the tape cools.